期刊
LEUKEMIA
卷 24, 期 1, 页码 44-50出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2009.228
关键词
CML; INNO-406; kinase profiling; chemical proteomics; kinase inhibitor
资金
- Leukemia and Lymphoma Society [5081-05]
- Austrian Federal Ministry for Science and Research (BMWF) [GZ200.142/I-VI/I/2006, GZ200.145/I-VI/I/2006]
- Austrian Science Fund (FWF) [P18737-B11]
- Austrian National Bank (ONB)
- Austrian Academy of Sciences (OAW)
Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML). This resistance is often caused by point mutations in the ABL kinase domain or by overexpression of LYN. The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently. Knowledge of its full target spectrum would provide the molecular basis for potential side effects or suggest novel therapeutic applications and possible combination therapies. We have performed an unbiased chemical proteomics native target profile of INNO-406 in CML cells combined with functional assays using 272 recombinant kinases thereby identifying several new INNO-406 targets. These include the kinases ZAK, DDR1/2 and various ephrin receptors. The oxidoreductase NQO2, inhibited by both imatinib and nilotinib, is not a relevant target of INNO-406. Overall, INNO-406 has an improved activity over imatinib but a slightly broader target profile than both imatinib and nilotinib. In contrast to dasatinib and bosutinib, INNO-406 does not inhibit all SRC kinases and most TEC family kinases and is therefore expected to elicit fewer side effects. Altogether, these properties may make INNO-406 a valuable component in the drug arsenal against CML. Leukemia (2010) 24, 44-50; doi:10.1038/leu.2009.228; published online 5 November 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据